2-Methyl-1-sulfamoyl-piperidin | 4108-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Methyl-1-sulfamoyl-piperidin
• 英文别名: 2-methyl-piperidine-1-sulfonic acid amide；1-Piperidinesulfonamide, 2-methyl-；2-methylpiperidine-1-sulfonamide
• CAS: 4108-91-2
• 化学式: C₆H₁₄N₂O₂S
• 分子量: 178.255
• InChiKey: RKAMIEKGILWGSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Methyl-1-sulfamoyl-piperidin 、 5-chloro-4-(cyclopentylmethoxy)-2-fluorobenzoic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 5-chloro-4-(cyclopentylmethoxy)-2-fluoro-N-((2-methylpiperidin-1-yl)sulfonyl)benzamide
  参考文献：
  名称：

  [EN] SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME
  [FR] INHIBITEURS DE CANAUX SODIQUES ET LEURS PROCÉDÉS DE CONCEPTION

  摘要：

  The invention provides compounds of formulae I, II, Ila, and III, as described herein, and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.

  公开号：

  WO2023028077A1

文献信息

• [EN] COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATIONS THEREOF AND USES THEREOF II<br/>[FR] COMPOSES, COMPOSITIONS CONTENANT CES COMPOSES, PREPARATION ET UTILISATIONS DE CES DERNIERS
  申请人：ASTRAZENECA AB

  公开号：WO2006033633A1

  公开（公告）日：2006-03-30

  Compounds of Formulae I, or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4 and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  公式I的化合物，或其药用盐：（I）其中R1、R2、R3、R4和G如规范中定义的那样，以及包括这些化合物的盐和药用组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理方面。
• Novel macrocyclic inhibitors of hepatitis C virus replication
  申请人：Blatt M. Lawrence

  公开号：US20070054842A1

  公开（公告）日：2007-03-08

  The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供一般式I至一般式VIII的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。本实施例还提供治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，这些方法通常涉及向需要治疗的个体施用一种主体化合物或组合物的有效量。
• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Blatt Lawrence M.

  公开号：US20120208995A1

  公开（公告）日：2012-08-16

  The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般式I至一般式VIII的化合物，以及包括药物组合物在内的组合物。实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，通常涉及向需要的个体施用所述化合物或组合物的有效量。
• Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
  申请人：Blatt Lawrence M.

  公开号：US20090148407A1

  公开（公告）日：2009-06-11

  The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供通式（I）到通式（VIII）的化合物，以及包括制药组合物在内的组合物，其中包括主体化合物。本实施例还提供治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述主体化合物或组合物的有效量。
• Novel macrocyclic inhibitors of Hepatitis C virus replication
  申请人：Intermune, Inc.

  公开号：EP2103623A2

  公开（公告）日：2009-09-23

  The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本发明的实施方案提供了通式(I)至通式(VIII)的化合物，以及包含主题化合物的组合物，包括药物组合物。本发明的实施方案进一步提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法一般涉及向有需要的个体施用有效量的主题化合物或组合物。